These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 31498127)
41. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893 [TBL] [Abstract][Full Text] [Related]
42. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Moreira J; Guimarães B; Rocha JF; Soares-da-Silva P Mov Disord; 2022 Nov; 37(11):2272-2283. PubMed ID: 36054562 [TBL] [Abstract][Full Text] [Related]
43. Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review. Katsaiti I; Nixon J J Parkinsons Dis; 2018; 8(2):217-231. PubMed ID: 29614697 [TBL] [Abstract][Full Text] [Related]
44. Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy. Annus Á; Vécsei L Drug Des Devel Ther; 2017; 11():143-151. PubMed ID: 28123288 [TBL] [Abstract][Full Text] [Related]
45. COMT Inhibitors in the Management of Parkinson's Disease. Fabbri M; Ferreira JJ; Rascol O CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995 [TBL] [Abstract][Full Text] [Related]
46. The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone. Leta V; van Wamelen DJ; Aureli F; Metta V; Trivedi D; Cortelli P; Rodriguez-Blazquez C; Rizos A; Ray Chaudhuri K J Neural Transm (Vienna); 2023 Jul; 130(7):925-930. PubMed ID: 37036498 [TBL] [Abstract][Full Text] [Related]
47. Opicapone for the treatment of Parkinson's disease. Rodrigues FB; Ferreira JJ Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566 [TBL] [Abstract][Full Text] [Related]
48. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718 [TBL] [Abstract][Full Text] [Related]
49. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
51. Opicapone for the treatment of Parkinson's disease: an update. Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L Expert Opin Pharmacother; 2019 Dec; 20(18):2201-2207. PubMed ID: 31670988 [No Abstract] [Full Text] [Related]
52. Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations. Berger AA; Robinson C; Winnick A; Izygon J; Jacob BM; Noonan MJ; Kaye AD; Kaye JS; Kaye AM; Cornett EM; Shah RJ; Viswanath O; Urits I Clin Drug Investig; 2022 Feb; 42(2):127-135. PubMed ID: 34935105 [TBL] [Abstract][Full Text] [Related]
53. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Larsen JP; Worm-Petersen J; Sidén A; Gordin A; Reinikainen K; Leinonen M; Eur J Neurol; 2003 Mar; 10(2):137-46. PubMed ID: 12603288 [TBL] [Abstract][Full Text] [Related]
54. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE. Cattaneo C; Sardina M; Bonizzoni E J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Kuoppamäki M; Leinonen M; Poewe W J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184 [TBL] [Abstract][Full Text] [Related]
56. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813 [TBL] [Abstract][Full Text] [Related]
57. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
58. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa. LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072 [TBL] [Abstract][Full Text] [Related]
60. Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis. Xie L; Qi X; Wang X; He B; Wang Y; Zhang W; Yu Z; Deng M; Liang S; Lü M Front Pharmacol; 2022; 13():1042992. PubMed ID: 36506576 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]